| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/09/2002 | EP1246623A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 10/09/2002 | EP1246622A1 Novel substituted benzimidazole dosage forms and method of using same |
| 10/09/2002 | EP1246621A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 10/09/2002 | EP1246618A1 N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid in iron chelating therapy |
| 10/09/2002 | EP1246617A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 10/09/2002 | EP1246590A1 Local prevention or amelioration of pain from surgically closed wounds |
| 10/09/2002 | EP1246538A1 Thickened oil compositions of edible oil |
| 10/09/2002 | EP1115391B1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| 10/09/2002 | EP1024798B1 Neomycin/disaccharide water solution for enteroclysis in hepatic encephalopathy |
| 10/09/2002 | EP1009411A4 Method and composition for treating sleep apnea |
| 10/09/2002 | EP0853477B1 At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| 10/09/2002 | EP0833620B1 Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| 10/09/2002 | EP0825863B1 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| 10/09/2002 | EP0769025B1 Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 10/09/2002 | CN1373808A Calpains and their use |
| 10/09/2002 | CN1373675A Composition for IVF |
| 10/09/2002 | CN1373672A Blocking immune response to foreign antigen using antagonist which binds to CD20 |
| 10/09/2002 | CN1373670A Tissue volume reduction |
| 10/09/2002 | CN1373668A Hybrid peptide modulate immune response |
| 10/09/2002 | CN1373667A Formulations for parenteral use of estramustine phosphate and amino acids |
| 10/09/2002 | CN1373666A Medicament with protective effect against oxidative-toxic substances, particularly against cardiotoxin substances |
| 10/09/2002 | CN1373662A 3(5)-amino-pyrazole derivs., process for their preparation and their use as antitumor agents |
| 10/09/2002 | CN1373659A Solid lipid formulations |
| 10/09/2002 | CN1373656A Dispersion formulations contg. lipase inhibitors |
| 10/09/2002 | CN1372926A Medicinal ointment containing zinc conjugated linoleate and sodium humate |
| 10/09/2002 | CN1092045C Vesicular complexes and methods of making and using same |
| 10/08/2002 | US6462091 A tertiary amine substituted with a monochlorinated diphenyl-ether, a phenylperfluoroethyl ether and a hydroxylated fluorinated alkane; synergistic with mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin or atorvastatin |
| 10/08/2002 | US6462086 Non-malignant disease treatment with Ras antagonists |
| 10/08/2002 | US6462084 Gamma vinyl gamma amino butyric acid; prolonged effect; irreversible enzyme inhibitor that raises endogenous levels without addiction |
| 10/08/2002 | US6462072 Such as 4,4-diphenylcyclohexl-1-(3,3-dimethyl-2-oxopentan-oyl)-pyrrolidine-2 -carboxylate; rotamase inhibitors; neuronal repair and regrowth; parkinson's disease, alzheimer's disease, amyotrophic lateral sclerosis |
| 10/08/2002 | US6462070 Photosensitizer conjugates for pathogen targeting |
| 10/08/2002 | US6462067 Administering histamine or salt derivative; preventing and/or reducing oxidative cellular and tissue damage; inflammatory diseases, including rheumatoid arthritis, crohn's disease, and adult respiratory distress syndrome |
| 10/08/2002 | US6462065 Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases |
| 10/08/2002 | US6462064 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias |
| 10/08/2002 | US6462057 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 10/08/2002 | US6462047 Containing 5- or 6-membered oxygen, nitrogen and/or sulfur heteroaryl group; angina, hypertension, respiratory distress, congestive heart failure, renal failure, atherosclerosis, inflammatory diseases, strokes, bronchitis, asthma |
| 10/08/2002 | US6462032 Cyclic regimens utilizing indoline derivatives |
| 10/08/2002 | US6462029 Diseases and/or conditions caused by circulating agents such as poisonous heavy metals, environmental toxins, calcium and cholesterol |
| 10/08/2002 | US6462025 Shel flife and convenient dispensing; for therapy of acne |
| 10/08/2002 | US6462024 Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart |
| 10/08/2002 | US6462020 N-formyl-met-leu-leu-phe-phe; inhibiting release of cytokines, histamines and leukotrienes; reducing adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils; rheumatoid arthritis |
| 10/08/2002 | US6462019 Inhibitors of proteasomal activity and production for stimulating bone growth |
| 10/08/2002 | US6462017 Method of reducing side effects of chemotherapy in cancer patients |
| 10/08/2002 | US6461855 Microtubule stimulated atpase activity; cancer and nervous system disorder diagnosis |
| 10/08/2002 | US6461846 Peptide for use in the treatment of alzhiemer's, inflammation, cancer and immune defects |
| 10/08/2002 | US6461822 Therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin il-1 and il-1 beta |
| 10/08/2002 | US6461642 Crystallization using supercritical or subcritical fluids |
| 10/08/2002 | US6461637 Method of administering liposomal encapsulated taxane |
| 10/08/2002 | US6461631 Biodegradable polymer composition |
| 10/08/2002 | US6461607 Probiotic, lactic acid-producing bacteria and uses thereof |
| 10/08/2002 | CA2231046C Human protein kinases hyak3 |
| 10/06/2002 | CA2378565A1 Crystal structure |
| 10/05/2002 | CA2380381A1 Combination treatment of multiple sclerosis (ms) other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |
| 10/03/2002 | WO2002077642A1 Mthod of screening drug for preventing/treating proliferative glomerular nephritis |
| 10/03/2002 | WO2002077336A1 Methods for forming hardened tubes and sheets |
| 10/03/2002 | WO2002077267A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 10/03/2002 | WO2002077266A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 10/03/2002 | WO2002077263A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 10/03/2002 | WO2002077261A2 Human potassium channel |
| 10/03/2002 | WO2002077237A2 Transporters and ion channels |
| 10/03/2002 | WO2002077217A2 Human dual specificity protein phosphatase 7-like protein |
| 10/03/2002 | WO2002077216A2 Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby |
| 10/03/2002 | WO2002077028A1 Polypeptides and nucleic acids for bolekine |
| 10/03/2002 | WO2002077023A2 A new essential downstream component of the wingless signalling pathway |
| 10/03/2002 | WO2002076989A1 Protein phosphate inhibitors |
| 10/03/2002 | WO2002076987A1 (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| 10/03/2002 | WO2002076979A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 10/03/2002 | WO2002076975A1 Chemical derivatives and their use as anti-telomerase agent |
| 10/03/2002 | WO2002076947A1 Mch antagonists and their use in the treatment of obesity |
| 10/03/2002 | WO2002076946A2 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
| 10/03/2002 | WO2002076929A1 Aryl and biaryl compounds having mch modulatory activity |
| 10/03/2002 | WO2002076548A2 Methods and apparatus for treating diseased tissue |
| 10/03/2002 | WO2002076510A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 10/03/2002 | WO2002076509A2 Preparation for the prophylaxis of restenosis |
| 10/03/2002 | WO2002076504A1 Remedies for inflammatory bowel diseases |
| 10/03/2002 | WO2002076501A2 Blood cell production via activation of the hemoglobin scavenger receptor |
| 10/03/2002 | WO2002076499A2 Combination treatment of pancreatic cancer |
| 10/03/2002 | WO2002076494A2 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS |
| 10/03/2002 | WO2002076486A2 Histidine-rich glycoprotein |
| 10/03/2002 | WO2002076484A2 Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 10/03/2002 | WO2002076482A2 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
| 10/03/2002 | WO2002076481A1 Composition and method of use in treating sexual dysfunction using cgmp-specific phosphodiesterase type 5 inhibitors |
| 10/03/2002 | WO2002076474A1 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 10/03/2002 | WO2002076472A2 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| 10/03/2002 | WO2002076471A1 Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| 10/03/2002 | WO2002076460A2 Use of propentofylline to control intraocular pressure |
| 10/03/2002 | WO2002076452A1 Use of melationin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 10/03/2002 | WO2002076450A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 10/03/2002 | WO2002076439A2 Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
| 10/03/2002 | WO2002076437A2 Methods for treating neurodegenerative diseases including alzheimer's |
| 10/03/2002 | WO2002076435A2 Lipid profile modulation with steroids |
| 10/03/2002 | WO2002076434A2 Nicotinic receptor agonists for the treatment of inflammatory diseases |
| 10/03/2002 | WO2002076400A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| 10/03/2002 | WO2002076398A2 Improved forms of pharmaceutically active agents and method for manufacture thereof |
| 10/03/2002 | WO2002076395A2 Agents and methods for treatment of cancer |
| 10/03/2002 | WO2002076391A2 Microbial feeds for aquaculture and agriculture |
| 10/03/2002 | WO2002076390A2 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 10/03/2002 | WO2002076388A2 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside |
| 10/03/2002 | WO2002076173A2 Inhibitors of glycosaminoglycans |
| 10/03/2002 | WO2002062297A3 Methods and compositions for modulating gluconeogenesis using pgc-1 |